Celltrion Usa
Chemicals & Related Products · New Jersey, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
1 Evertrust Plz Ste 1207, Jersey City, N...Phone Number
(201) 578-4188Website
www.celltrionusa.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
3
1
1
1
1
About Celltrion Usa
Celltrion USA, established in 2018 and headquartered in Jersey City, is dedicated to enhancing patient access to high-quality biopharmaceuticals. The company leverages its unique heritage in biotechnology, supply chain excellence, and sales capabilities to provide advanced therapies for patients in the US. Their product offerings include biologics such as Zymfentra, Yuflyma, Vegzelma, SteQeyma, Osenvelt, and Stoboclo. Celltrion USA aims to improve patient welfare and healthcare access through its innovative solutions.Explore more
Celltrion Usa Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Celltrion Usa your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Celltrion Usa
Earning: See what the market has to say on Celltrion Usa recently announced quarterly report
Check if Celltrion Usa has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Celltrion Usa launches new products
Click to see if Celltrion Usa had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Celltrion Usa has new funding data
Celltrion Usa, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Check out if Celltrion Usa is spiking on competitors!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Celltrion Usa
Compare insights from companies similar to Celltrion Usa, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Celltrion Usa is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Celltrion Usa is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Celltrion Usa.
Celltrion Usa Tech Stack
A closer look at the technologies used by Celltrion Usa
See more technologies
Most Recent Scoops
Hiring Plans
Celltrion Usa has more open roles in Medical & Health than it has had at any time in the past 12 months. Areas of expertise include: Clinical Medicine, Gastroenterology, Medical Terminology, Pharmaceutical Sciences, PhRMA Code, Life Sciences, and Health Sciences.
Hiring Plans
Hiring Plans
Celltrion Usa has more open roles in Sales than it has had at any time in the past 6 months. Areas of expertise include: Sales Analysis.
Hiring Plans
New Hire
Executive Move
Todd Winge has recently joined the organization as Chief Executive Officer.
Executive Moves, New Hire
Hiring Plans
Hiring Plans
Celltrion Usa News & Media
Celltrion announces U.S. availability of AVTOZMA® (tocilizumab-anoh) subcutaneous (SC) formulation
AVTOZMA® (tocilizumab-anoh) is among the first wave of tocilizumab biosimilars with both intravenous (IV) and subcutaneous (SC) formulations approved and commercially available in the United States The launch of AVTOZMA SC further diversifies Celltrion's immunology portfolio beyond...Celltrion announces U.S. FDA approval of 300mg strength of OMLYCLO® (omalizumab-igec), the first and only FDA-approved interchangeable biosimilar to XOLAIR®
FDA approval of OMLYCLO® (omalizumab-igec) 300 mg/2 mL solution in a single-dose prefilled syringe for subcutaneous injection expands dosing flexibility and supports tailored treatment for individual patients with certain allergic diseases OMLYCLO® (omalizumab-igec) is the first and only biosimilar designated as interchangeable with XOLAIR® (omalizumab); The FDA previously approved OMLYCLO® 75 mg/0.5 mL and 150 mg/mL in a single-dose prefilled syringe for subcutaneous injection in March 2025 INCCelltrion announces publication of post-hoc analysis of LIBERTY-CD study of ZYMFENTRA® (infliximab-dyyb), indicating consistent efficacy across disease location, including the terminal ileum in Clinical Gastroenterology and Hepatology journal
Findings from the post-hoc analysis of LIBERTY-CD study indicates efficacy of ZYMFENTRA® (subcutaneous infliximab) regardless of disease location, consistent across ileum-dominant and colon-dominant Crohn's disease (CD) Findings support the therapeutic potential of ZYMFENTRA in addressing...U.S. FDA grants interchangeability designation to Celltrion's denosumab biosimilars, STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo)
The U.S. FDA approved STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo) as interchangeable with the reference products PROLIA® (denosumab) and XGEVA® (denosumab), respectively, for all approved indications, effective as of October 29, 2025 The interchangeability (IC) designations...
Read more news
Top Chemicals & Related Products Companies
See more top companies
Frequently Asked Questions Regarding Celltrion Usa
Sign Up For FreeTo access detailed company insights
Celltrion USA, established in 2018 and headquartered in Jersey City, is dedicated to enhancing patient access to high-quality biopharmaceuticals. The company leverages its unique heritage in biotechnology, supply chain excellence, and sales capabilities to provide advanced therapies for patients in the US. Their product offerings include biologics... Read More
